
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: September 13, 2021

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

On September 13, 2021, Legend Biotech Corporation (the “Company”) announced the start of a Phase 1 clinical trial in the United States for LB1901, an investigational autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). LB1901 targets CD4, a surface membrane glycoprotein uniformly expressed in most TCL subtypes. The trial follows the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application submitted by Legend Biotech.

The Phase 1 trial (LB1901-TCL-001), which is being led by Dr. Swaminathan P. Iyer, Professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, is an open label, multi-center and multicohort clinical study of LB1901 in patients with relapsed or refractory (RR) PTCL or CTCL (NCT04712864)—patients with histologically confirmed CD4+ RR PTCL (PTCL not otherwise specified, or PTCL-NOS, and angioimmunoblastic T cell lymphoma, or AITL) or RR CTCL (mycosis fungoides and Sézary syndrome). Recruitment in the trial has begun in the U.S. The primary objectives are to characterize the safety and tolerability of LB1901 and determine the optimal dose.

T-cell lymphoma is a heterogeneous group of lymphoid malignancies that account for less than 15 percent of non-Hodgkin’s lymphoma cases in the US. PTCL comprises subtypes that are uncommon and often aggressive, with a 5-year overall survival of only 39%. CTCL are a group of T-cell malignancies that occur primarily in the skin. Despite current treatment options, a substantial proportion of patients with PTCL or CTCL experiences relapse. A high unmet medical need remains for patients with relapsed or refractory PTCL and CTCL.

On September 13, 2021, the Company issued a press release relating to the foregoing, which is attached to this Form 6-K as Exhibit 99.1.

On September 13, 2021, the Company also posted an updated version of its corporate presentation, reflecting updates to certain near term target dates, to its website.

This Form 6-K (other than Exhibits 99.1 and 99.2 hereto) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-257625 and 333-257609) and Form S-8 (File No. 333-239478).

Cautionary Note Regarding Forward-Looking Statements

Statements in this report on Form 6-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; the anticipated timing of, and ability to progress, the Phase 1 clinical trial of LB1901 in RR PTCL and RR CTCL; patient enrollment in the LB1901 Phase 1 clinical trial; and the potential benefits of LB1901 or any of our other product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 2, 2021. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

EXHIBIT INDEX

Exhibit	Title
99.1	Press Release, dated September 13, 2021.
99.2	Corporate Presentation – September 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION
(Registrant)

September 13, 2021

By: /s/ Ying Huang
Ying Huang, Ph.D.
Chief Executive Officer and Chief Financial Officer

Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

SOMERSET, N.J.--(BUSINESS WIRE)--September 13, 2021--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced the start of a Phase 1 clinical trial in the United States for LB1901, an investigational autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). LB1901 targets CD4, a surface membrane glycoprotein uniformly expressed in most TCL subtypes. The trial follows the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application submitted by Legend Biotech.

The Phase 1 trial is being led by Dr. Swaminathan P. Iyer, Professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, and is an open label, multi-center and multicohort clinical study in patients with relapsed or refractory PTCL or CTCL (NCT04712864). Recruitment in the trial has begun in the U.S.

“We are excited by the promise of LB1901, and we look forward to further evaluating the safety and tolerability of LB1901. Determining the optimal dose for subsequent evaluation is one of the key objectives of this trial,” said Dr. Lida Pacaud, Vice President of Clinical Development at Legend Biotech. “The number of patients who relapse or are refractory to current TCL treatments is significant, and this trial will provide important information about the potential of CAR-T therapy to treat this disease.”

T-cell lymphoma is a heterogeneous group of lymphoid malignancies that account for less than 15 percent of non-Hodgkin’s lymphoma cases in the US.^{i,ii} PTCL comprises subtypes that are uncommon and often aggressive, with a 5-year overall survival of only 39%.^{iii,iv} CTCL are a group of T-cell malignancies that occur primarily in the skin.^v Despite current treatment options, a substantial proportion of patients with PTCL or CTCL experiences relapse. A high unmet medical need remains for patients with relapsed or refractory PTCL and CTCL.

About the Clinical Development Program

LB1901-TCL-001 (NCT04712864) is a Phase 1 open-label, multicenter study of LB1901 in patients with histologically confirmed CD4+ RR PTCL (PTCL not otherwise specified, or PTCL-NOS, and angioimmunoblastic T cell lymphoma, or AITL) or RR CTCL (mycosis fungoides and Sézary syndrome). The primary objectives are to characterize the safety and tolerability of LB1901 and determine the optimal dose.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; the anticipated timing of, and ability to progress, the Phase 1 clinical trial of LB1901 in RR PTCL and RR CTCL; patient enrollment in the LB1901 Phase 1 clinical trial; and the potential benefits of LB1901 or any of our other product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 2, 2021. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

i Scherer LD, Brenner MK, Mamonkin M. Chimeric antigen receptors for T-cell malignancies. *Frontiers in Oncology*. 2019 March;9(article 126):1-10.

ii American Cancer Society. Types of T-cell Lymphoma. Available at: <https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/t-cell-lymphoma.html>. Accessed August 2021.

iii Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, et al. T-cell lymphoma: Recent advances in characterization and new opportunities for treatment. *J Natl Cancer Inst*. 2017;109(2):1-9.

iv Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline based chemotherapy regimens for peripheral T-cell lymphoma. *ISRN Hematol*. 2011;2011:623924.

v Scarfo I, Frigault M, Maus M. CAR-based approaches to cutaneous T-cell lymphoma. *Frontiers in Oncology*. 2019;9(article 259):1-6.

Contacts

Investor Contacts:

Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com

Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech
crystal.chen@legendbiotech.com

Press Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025

Inspired by the
human element
to advance cell therapy

September 2021



Disclaimer

This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independent source.

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, but are not limited to, statements relating to the Company's strategies and objectives; the anticipated timing of, and ability to progress, clinical trials; the ability to make, and the timing of, regulatory submissions in the United States, Europe and Asia, including Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel) for relapsed or refractory multiple myeloma (RRMM), the submission of a marketing authorisation application (MAA) for cilta-cel to the European Medicines Agency (EMA), and the submission of an Investigational New Drug (IND) for LB1901 in relapsed or refractory T-Cell Lymphoma (TCL); the ability to generate, analyze and present data from clinical trials; patient enrollment; anticipated timing regarding regulatory approvals by the FDA, EMA or Center for Drug Evaluation (CDE); and the potential benefits of Legend Biotech's product candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of the Company's Annual Report filed with the Securities and Exchange Commission on April 2, 2021.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected.

Any forward-looking statements contained in this presentation speak only as of the date of this presentation. None of the Company nor any of its affiliates, advisers, or representatives has any obligation and does not undertake to update any forward-looking statements to reflect future events or circumstances.

Legend Highlights



7

Years
Since Inception

>900



Employees

10+



Pipeline Programs Covering:

- Hematologic malignancies
- Solid tumors
- Infectious diseases

4



R&D Platforms:

- Autologous CAR-T
- Allogeneic CAR-T
- TCR
- NK

3

Global

Manufacturing Sites:

- United States
- EU*
- China




\$663



Million

in Cash and Cash Equivalents and Time
Deposits as of June 30, 2021

*EU manufacturing site: Construction in progress



Cell Therapy Platform Overview

We Are A Fully Integrated Global Cellular Therapy Company



COMPELLING DATA WITH INNOVATIVE PIPELINE

- Lead product candidate ciltacabtagene autoleucl (cilta-cel) may have the potential to deliver deep and durable anti-tumor responses in RRMM
- Broad portfolio of earlier-stage autologous product candidates targeting both hematologic and solid cancers, as well as allogeneic CAR-T approaches

FUTURE PIPELINE

AML

LYMPHOMA

GASTRIC
CANCER

OVARIAN
CANCER

INFECTIOUS
DISEASE

GLOBAL COLLABORATION WITH JANSSEN*

- Global collaboration with Janssen for the development of cilta-cel established December 2017
 - Received an upfront payment of \$350 million and a total of \$200 million in milestone payments to date
 - Up to an additional \$1,150 million in potential future milestone payments



INTEGRATED CELL THERAPY PLATFORM

- In-house antibody generation and CAR-T specific functional screening technologies
- Early clinical proof-of-concept, leveraging KOL relationships in China, the US and globally
- Building large-scale manufacturing facilities in the United States, Europe and China
- >900 employees worldwide in US, China and Europe

RRMM, Relapsed and/or Refractory Multiple Myeloma; AML, acute myeloid leukemia; KOL, key opinion leaders
*Legal entity to the agreement is Janssen Biotech, Inc.



Legend Biotech's Global R&D Strategy



***With a Presence in Major Geographies,
our Mission is to Improve the Lives of Patients Worldwide***


CAR, Chimeric Antigen Receptor; TCR, T-Cell Receptor



End-to-End R&D Capability

High-throughput antibody screening and engineering capability including single-domain antibodies generated from Llama and conventional antibodies


Robust *in vitro* and *in vivo* screening platforms to prioritize pipeline assets



Proprietary methodology to optimize the selection of binding domains and design CAR-T constructs with two or more antigen-binding domains

Efficient clinical translation, leveraging deep relationships with KOLs in US and China

Robust Pipeline of the Next Generation Cell Therapies




AML, acute myeloid leukemia; BCMA, B-cell maturation antigen; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphomas; MM, multiple myeloma; MSLN, mesothelin; NSCLC, non small cell lung cancer; RoW, Rest of World; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; TCL, T-cell lymphoma

*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson
 *LEGEND-2 trial is completed with ongoing follow-up

Legend and Janssen Global Collaboration

Worldwide collaboration and license agreement to develop and commercialize cilta-cel



Highly Experienced Management Team



YING HUANG
Chief Executive Officer/ Chief Financial Officer



Lida Pacaud
Clinical Development



DONG GENG
Early-stage Drug Development



STEVE GAVEL
Commercial Development



ALAN KICK
Global Quality



ELIZABETH GOSEN
Global Manufacturing



YUHONG QIU
Global Regulatory



MEETA CHATTERJEE
Global Business Development



Lori Macomber
Finance



FRANK FAN
Chief Scientific Officer & Co-Founder



SIMON WU
Research & Development



TRACY LUO
Clinical Development



CHONG YANG
Commercial Development





**Cilta-cel
Clinical
Development**

Multiple Myeloma: Blood Cancer with a High Unmet Need



3RD MOST COMMON BLOOD CANCER

accounting for **18%** of all hematologic cancer¹⁻³



176,404

NEW CASES WORLDWIDE IN 2020,
accounting for 1% of worldwide
new cancer cases^{3,4}



US: Incidence is
32,119, with
mortality of 13,426⁵



EUROPE: Incidence is
50,918, with
mortality of 32,495⁶




CHINA: Incidence is
21,116, with
mortality of 16,182⁷

**POOR SURVIVAL OUTCOMES IN MULTIPLE
REFRACTORY MM**

Median OS < 12 months

in patients refractory to anti-CD38, ≥ 1 PI(s) and / or ≥ 1 IMiD(s)⁸



CI, confidence interval; PI, Proteasome Inhibitor; IMiD, immunomodulatory drug; MM, multiple myeloma; OS, overall survival

1. Cancer Stat Facts: Myeloma. <https://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed June 2021. 2. Facts and Statistics. <https://www.ils.org/facts-and-statistics/facts-and-statistics-overview>. Accessed June 2021. 3. Globocan 2020 World Fact Sheet: <https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf>. Accessed June 2021. 4. Globocan 2020 World Fact Sheet: World. <https://gco.iarc.fr/today/data/factsheets/populations/90-world-fact-sheets.pdf>. Accessed June 2021. 5. Globocan 2020 World Fact Sheet: United States of America. <http://gco.iarc.fr/today/data/factsheets/populations/940-united-states-of-america-fact-sheets.pdf>. Accessed June 2021. 6. Globocan 2020 World Fact Sheet: Europe. <https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf>. Accessed June 2021. 7. Globocan 2020 World Fact Sheet: China. <https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf>. Accessed June 2021. 8. Gandhi UH, et al. Leukemia. 2019;33:2266-75.

First-in-Human, Phase 1, Dose Finding Study in RRMM LEGEND-2: LCAR-B38M CAR-T cells



Key Inclusion Criteria^{1,2}

- Active MM defined by IMWG criteria with documented disease progression during or within 12 months of most recent anti-MM drugs or auto-HSCT
- Relapsed on prior regimens

Enrollment

- Total: 74 patients (4 sites in China)
- Xi'an: N=57, Wang, et al. ASH 2019
- JS/RJ/CZ sites: N=17, Chen, et al. ASH 2019

Preconditioning

- Cyclophosphamide only (Xi'an, Jiangsu)^{1,2}
- Cyclophosphamide + fludarabine (Changzheng, Ruijin)²

Administered dose (CAR+ viable T cells/kg)

- Xi'an¹ (median)= 0.5×10^8 (0.07- 2.1×10^8)
- RJ/CZ/JS² (mean)= 0.70×10^8 (0.2- 1.5×10^8)

Safety & Tolerability

- Cita-cel CAR-T cells displayed a safety profile consistent with other safety reports of BCMA-targeting CAR-T cell therapy^{1,2}


Data cut-off: 31 July 2019 (N=57) and 31 October 2019 (N=17);

1. Wang B-Y et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 579; 2. Chen L, et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 1858.

LEGEND-2: Long-Term Deep Responses and High Response Rate


Xi'an: Best overall response (N=57)¹

- mDOR= 27.0 months (mDOR for CR= 29.1 months)¹
- Median time to initial response= 1 month¹
- mPFS= 19.9 months (mPFS for CR= 28.2 months)¹
- mOS = 36.1 months (mOS for CR not reached)¹



Ruijin (RJ), Jiangsu (JS), Changzheng (CZ): Best overall response (N=17)²

- Median time to initial response= 1 month²
- mPFS = 18 months; mOS= not reached²



Data cut-off: 31 July 2019 (N=57) and 31 October 2019 (N=17); Xi'an: NE patient died of PE/ACS prior to first evaluation. RJ, JS, CZ: For NE patients, 1 patient died on Day 13 due to CRS and tumor lysis syndrome; 1 patient received chemotherapy prior to first assessment and was censored. ^aORR=PR or better; response assessed per International Myeloma Working Group criteria. CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; mDOR, median duration of response; MRD, minimal residual disease; ORR, overall response rate; mPFS, median progression free survival; mOS, median overall survival.

1. Wang B-Y et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 579; 2. Chen L, et al. ASH Annual Meeting; December 7-10, 2019; Orlando, FL, Abstract 1858.

CARTITUDE-1: Phase 1b/2 Study Design

Primary Objectives


- Phase 1b: Characterize the safety of ciltacabtagene autoleucel (cilta-cel) and confirm the recommended phase 2 dose
- Phase 2: Evaluate the efficacy of cilta-cel by ORR

Key Inclusion Criteria

- Progressive MM per IMWG criteria
- ECOG PS ≤ 1
- Measurable disease
- Received ≥ 3 prior therapies or double refractory
- Prior PI, IMiD, anti-CD38 therapy

Administered dose

- Median administered dose:
0.71x10⁶ (0.51– 0.95x10⁶) CAR+ viable T cells/kg



Cy, cyclophosphamide; ECOG PS, Eastern Cooperative Oncology Group performance status; Flu, fludarabine; IMiD, immunomodulatory drug; IMWG, International Myeloma Working Group; PI, proteasome inhibitor; PD, pharmacodynamic; PK, pharmacokinetic; MM, multiple myeloma
Data cut-off: Feb 11, 2021; ^a Treatment that was received previously and resulted in at least stable disease.
1. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005; 2. Clinicaltrials.gov website (NCT03548207). <https://clinicaltrials.gov/ct2/show/NCT03548207>. Accessed June 2021

CARTITUDE-1: Baseline Characteristics

Characteristic (N=97)

Age, median (range) years	61.0 (43–78)
Male, n (%)	57 (58.8)
Black/African American, n (%)	17 (17.5)
All plasmacytomas, ^a n (%)	19 (19.6)
Extramedullary plasmacytomas, n (%)	13 (13.4)
Bone-based plasmacytomas, n (%)	6 (6.2)
Bone-marrow plasma cells ≥60%, n (%)	21 (21.9)
Years since diagnosis, median (range)	5.9 (1.6–18.2)
High-risk cytogenetic profile, n (%)	23 (23.7)
del17p	19 (19.6)
t(14;16)	2 (2.1)
t(4;14)	3 (3.1)
Tumor BCMA expression ≥50%, n (%)	57 (91.9) ^b

Characteristic


Prior lines of therapy, median (range)	6.0 (3–18)
Prior lines of therapy, n (%)	
3	17 (17.5)
4	16 (16.5)
≥5	64 (66.0)
Previous stem-cell transplantation, n (%)	
Autologous	87 (89.7)
Allogeneic	8 (8.2)
Triple-class exposed, ^c n (%)	97 (100)
Penta-drug exposed, ^d n (%)	81 (83.5)
Triple-class refractory ^c	85 (87.6)
Penta-drug refractory ^d	41 (42.3)
Refractory status, n (%)	
Carfilzomib	63 (64.9)
Pomalidomide	81 (83.5)
Anti-CD38 antibody	96 (99.0)
Refractory to last line of therapy, n (%)	96 (99.0)

Data cut-off: Feb 11, 2021; BCMA, B-cell maturation antigen; IMiD, immunomodulatory drug; PI, proteasome inhibitor.

^aAll plasmacytomas include extramedullary and bone-based plasmacytomas. ^bDenominator n=62, the number of evaluable samples; BCMA expression detected in all evaluable samples. ^cAt least 1 PI, at least 1 IMiD, and 1 anti-CD38 antibody. ^dAt least 2 PIs, at least 2 IMiDs, and 1 anti-CD38 antibody.

Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005

CARTITUDE-1: Overall Response Rate




With longer follow-up, responses deepened with increasing rate of sCR

- Median time to first response: 1 month (range, 0.9–10.7)
- Median duration of response: 21.8 months (95% CI, 21.8–NE); not reached in patients with sCR
- Response rates were comparable (range, 95–100%) across different subgroups (eg, number of prior lines of therapy, refractoriness, extramedullary plasmacytomas, and cytogenetic risk)^a
- 91.8% of 61 evaluable patients were MRD negative^b
 - Median time to MRD 10⁻⁵ negativity: 1 month (range, 0.8–7.7)

Data cut-off: Feb 11, 2021; CR, complete response; MRD, minimal residual disease; ORR, overall response rate; sCR, stringent complete response; VGPR, very good partial response. ORR assessed by independent review committee. ^aSubgroups by number of prior lines of therapy (≤ 4 , >4), refractoriness (triple-class, penta-drug), cytogenetic risk (high risk, standard risk), baseline bone marrow plasma cells ($\leq 30\%$, >30 to $<60\%$, $\geq 60\%$), baseline tumor BCMA expression (\geq median, $<$ median), and baseline plasmacytomas (including extramedullary and bone-based). ^bMRD was assessed in evaluable samples (ie, patients with identifiable clone at baseline and sufficient cells for testing at 10⁻⁵ threshold in post-treatment samples) by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) in all treated patients at Day 28, and at 6, 12, 18, and 24 months regardless of the status of disease measured in blood or urine. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005

CARTITUDE-1: Progression Free Survival



Data cut-off: Feb 11, 2021; NE, not estimable; PFS, progression-free survival; OS, overall survival; sCR, stringent complete response. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005

CARTITUDE-1: Safety

	N = 97	
	Any Grade	Grade 3/4
Hematologic AEs, (≥30%), n (%)		
Neutropenia	93 (95.9)	92 (94.8)
Anemia	79 (81.4)	66 (68.0)
Thrombocytopenia	77 (79.4)	58 (59.8)
Leukopenia	60 (61.9)	59 (60.8)
Lymphopenia	51 (52.6)	48 (49.5)
Non-hematologic AEs (≥30%), n (%)		
Hypocalcemia	31 (32.0)	3 (3.1)
Hypophosphatemia	30 (30.9)	7 (7.2)
Fatigue	36 (37.1)	5 (5.2)
Cough	34 (35.1)	0
CAR-T associated AEs, n (%)		
CRS ^a	92 (94.8)	4 (4.1)
Neurotoxicity	20 (20.6)	9 (9.3)

- **No new safety signals with longer follow-up**
- **CRS**
 - 94.6% of patients experienced low-grade CRS (n=92)
 - Median time to onset of 7 days (range, 1-12)
 - Median duration of 4 days (range, 1-97)^b and resolved in 91 (98.9%) patients within 14 days of onset
- **Neurotoxicity**
 - 20.6% of patients experienced neurotoxicity in total with overlap between ICANS and Other Neurotoxicities (Grade ≥3: 10.3%)
 - ICANS observed in 16.5% (Grade ≥3: 2.1%)
 - Other Neurotoxicities^c observed in 12.4% (Grade ≥3: 9.3%)
- **6 treatment-related deaths as assessed by the investigator^d**


Data cut-off Feb 11, 2021; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis. ^aCRS was graded using Lee et al. (*Blood* 2014) in the phase 1b portion of the study and ASTCT in phase 2; in this combined analysis, Lee et al. criteria were mapped to ASTCT criteria for patients in the phase 1b portion. ^bThe patient with 97-day duration died due to CRS/HLH. ^cEvents not reported as ICANS (ie, onset after a period of recovery from CRS and/or ICANS). ^dThere were 21 study deaths: 6 were treatment-related as assessed by the investigator, the remaining were due to AEs unrelated to treatment (n=5) and disease progression (n=10) Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005

CARTITUDE-2: Multicohort Study

Cohort A: 1 – 3 prior lines, lenalidomide refractory RRMM

- CARTITUDE-2 is a phase 2, multicohort, open-label study assessing the efficacy and safety of cilta-cel in patients with multiple myeloma in various clinical settings

BCMA-binding domains



Cilta-cel (CAR-T)

Cohort A:

- Cohort A patients had progressive MM after 1–3 prior lines of therapy, and were refractory to lenalidomide
- Despite advances continued unmet need with mPFS of 9.9 months (DPd)¹


Primary objectives

- Minimal residual disease (MRD) 10^{-5} negativity

Secondary objectives

- ORR, duration of response, time and duration of MRD negativity, and incidence and severity of adverse events


Study Design



CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; Cy, cyclophosphamide; Flu, fludarabine; MM, multiple myeloma; PD, pharmacodynamics; PK, pharmacokinetics
¹mPFS for lenalidomide refractory patients, Dimopoulos MA et al. Lancet Oncol. 2021;22:801-812

CARTITUDE-2: Phase 2 Multi-Cohort Study

- Cohort A included 20 patients who had progressive MM after 1–3 prior lines of therapy and were refractory to lenalidomide
- Median prior lines of therapy: 2 (range, 1-3); 1 patient treated in an outpatient setting




- No progression of disease at median follow-up of 5.8 months (range 2.5-9.8)
- All patients (n=4) with MRD-evaluable^b samples at the 10⁻⁵ threshold were MRD negative at data cut-off
- The safety profile was manageable
 - CRS occurred in 85% (n=17); mostly grades 1/2; median time to CRS onset was 7 days (range, 5–9)
 - Neurotoxicities occurred in 20% (n=4) of patients; no grade ≥3; no incidence of movement and neurocognitive TEAEs
 - 1 death occurred 100 days after infusion due to COVID-19 (assessed as tx related by the investigator)

Data cut-off date: Jan 2021; ^aPatient who did not respond had stable disease. ^bMRD was assessed in evaluable samples (ie, patients with identifiable clone at baseline and sufficient cells for testing at 10⁻⁵ threshold in posttreatment samples) by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) in all treated patients. CR, complete response; MRD, minimal residual disease; ORR, overall response rate; PR, partial response; sCR, stringent complete response; TEAE, treatment-emergent adverse events; VGPR, very good partial response. Agha M, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8013.

CARTITUDE Program: Safety

Successful new patient management strategies have been implemented in the CARTITUDE program to prevent and reduce the incidence of neurotoxicity¹⁻³




AE, adverse event; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; TEAE, treatment-emergent AE.

^aTwo patients with ongoing symptoms continued to improve at the time of data cutoff; patient management strategies were implemented, including enhanced bridging therapy to reduce baseline tumor burden, early aggressive treatment of CRS and ICANS, handwriting assessments for early detection of neurotoxicity symptoms, and extended monitoring and reporting time for neurotoxicity beyond the first 100 days post-cilta-cel infusion. ^bDefined as having high tumor burden when any of the following parameters were met: bone marrow plasma cell $\geq 80\%$, serum M-spike ≥ 5 g/dL, serum free light chain ≥ 5000 mg/L. ^cIncluded patients treated in earlier and later line settings across the CARTITUDE program.

1. Usmani S, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8005. 2. Agha M, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8013. 3. Einsele H, et al. ASCO Annual Meeting (Virtual). June 4-8, 2021. Abstract 8028

Clinical Program: Cilta-cel Studies in Multiple Myeloma



ASCT, autologous stem cell transplant; DPd, daratumumab, pomalidomide, dexamethasone; EU, European Union; JP, Japan; PVd, pomalidomide, bortezomib, dexamethasone; RRMM, relapsed and/or refractory multiple myeloma; SoC, standard of care; US, United States; VRd, bortezomib, lenalidomide, dexamethasone
¹ NCT03090659. Clinicaltrials.gov website: <https://clinicaltrials.gov/ct2/show/NCT03090659>. Accessed June 2021. ² NCT03548207. Clinicaltrials.gov website: <https://clinicaltrials.gov/ct2/show/NCT03548207>. Accessed June 2021. CARTITUDE-1 is global registrational study. ³ NCT03758417. Clinicaltrials.gov website: <https://clinicaltrials.gov/ct2/show/NCT03758417>. Accessed June 2021. CARTIFAN-1 is registrational study for China only. ⁴ NCT04133636. Clinicaltrials.gov website: <https://clinicaltrials.gov/ct2/show/NCT04133636>. Accessed June 2021. ⁵ NCT04181827. Clinicaltrials.gov website: <https://clinicaltrials.gov/ct2/show/NCT04181827>. Accessed June 2021. ⁶ NCT04923893. Clinicaltrials.gov website: <https://clinicaltrials.gov/ct2/show/NCT04923893>. Accessed June 2021. CARTITUDE-5 is global registrational study.

Global Manufacturing Footprint

US Facilities



Raritan, NJ

BCMA US / EU / JP / ROW
Launch/ Commercial Site

- ✓ GMP Operational



Somerset, NJ

US / EU / JP Legend Clinical
Supply Site

- construction ongoing

EU Facilities



Ghent, Belgium

Future Commercial Site

- Construction in progress



Ghent, Belgium

Future Commercial Site

- Construction in progress

China Facilities



Nanjing

BCMA China Launch Site &
Legend Clinical Supply Site

- ✓ GMP Operational



Nanjing 75-acre

Future Commercial Site

- Construction in progress

Building E

Future Potential Milestone Payments



Future Potential Milestones

Clinical Milestones: \$105M

\$105 million for the achievement of specified future development milestones

Regulatory Milestones: \$710M

\$710 million for the achievement of specified regulatory milestones

Commercial Milestones: \$210M

\$210 million for the achievement of specified net trade sales milestones.

Manufacturing Milestones: \$125M

Further milestone payments of up to \$125 million for the achievement of specified manufacturing milestones

Program Areas of Development

Legend Biotech is utilizing the extensive cell therapy experience of our leadership and R&D staff, global clinical partners, and expanding research facilities to realize the potential of cell therapy to treat diseases that are thought to be incurable, such as hematologic malignancies, solid tumors and infectious diseases.



LB1901: Investigational CAR-T for T Cell Lymphoma

MoA/ Scientific Rationale

- LB1901 targets CD4 antigen that is expressed in most T cell lymphoma (TCL) subtypes and in subsets of normal immune cells
- LB1901 is a CD8-enriched anti-CD4 CAR-T and contains a unique binder to CD4 leading to potential elimination of CD4+tumor cells

Target

- CD4 is a surface membrane glycoprotein expressed at high levels on TCL and a subtype of normal T cells¹
- Anti-CD4 mAb have been investigated in clinical studies for TCL²

Clinical Development

- US IND cleared with FDA
- Ongoing Phase 1 studies in US and China
- Patient population: relapsed/refractory PTCL and CTCL patients

CD, cluster of differentiation; CAR, chimeric antigen receptor; CTCL, cutaneous T-cell lymphoma; FDA, Food & Drug Administration; IND, investigational new drug application; mAb, monoclonal antibody; PTCL, peripheral T-cell lymphoma
1. Scherer LD, et al. *Front Oncol.* 2019;9:126; 2. Knox S, et al. *Blood.* 1996;87:893-899.

LB1908: Investigational CAR-T for Gastric Cancer

MoA/ Scientific Rationale

- LB1908 targets Claudin (CLDN) 18.2 through high-affinity VHH antibody
- VHH antibody, identified via in-house, selectively binds to CLDN 18.2

Target

- Claudins are a family of tight junction proteins¹
- CLDN18.2 is commonly expressed on multiple cancers including gastric cancer²

Clinical Development

- Phase I clinical study in China is ongoing for the treatment of adult patients with advanced gastric cancer
- US IND is being developed with planned submission in 1H2022

LB1905: Investigational Allogeneic CAR-T

MoA/ Scientific Rationale

- LB1905 targets CD20 that is expressed in B cell lymphoma
- LB1905 applied Legend UniCAR technology which is an unique non-gene-editing allogeneic CAR-T platform
- Simple and efficient manufacturing promote product homogeneity and accessibility


Target

- CD20 is mainly expressed in pre-B cells and mature B cells. It is expressed in more than 95% of B-cell lymphomas and not in hematopoietic stem cells, plasma cells, and other normal tissues

Clinical Development

- Allogeneic CD20 targeted product for the treatment of adult patients with recurred NHL
- Promising allogeneic platform that can potentially be leveraged in Legend clinical development programs

Near-Term Targets for Legend Biotech



Investment Highlights



Global Collaboration

Global collaboration with Janssen for the development of cilta-cel with ongoing clinical trials



Promising Clinical Data

Deep and durable anti-tumor responses observed in heavily pretreated patients with MM; BLA for cilta-cel submitted to US FDA (PDUFA target action date Nov 29, 2021); MAA for cilta-cel submitted to EMA



Fully Integrated Platform


End-to-end R&D and manufacturing capabilities with two core technologies (CAR and TCR) and two platforms (Autologous and Allogeneic)



Strong Management

Experienced team with broad involvement in biopharmaceutical drug discovery, development and commercialization

*In the world of cell therapy,
some biotechs have an Eastern perspective.
Others have a Western perspective.*



We are bridging the gap between *East and West.*



Thank You !